Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncopeptides AB ( (SE:ONCO) ) has provided an update.
Oncopeptides AB has announced a strategic partnership with SD Pharma to expand the reach of its flagship drug, Pepaxti, in Spain. This collaboration aims to enhance Oncopeptides’ commercial presence in Spanish hospitals, leveraging SD Pharma’s expertise in oncology and hematology. The partnership is expected to significantly advance Oncopeptides’ goal of addressing unmet medical needs in the cancer treatment landscape, with activities commencing in Q3 2025 on a success-based model.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. Utilizing its proprietary Peptide Drug Conjugate platform, the company develops compounds that deliver cytotoxic agents into cancer cells. Oncopeptides’ flagship drug, Pepaxti, is being commercialized in Europe, with partnerships extending to South Korea, the Middle East, and Africa. Founded in 2000, the company operates in several European countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 3,836,944
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.21B
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.